BioLineRx Ltd. (BLRX) Form 6-K — Nov 16, 2026
BioLineRx and partner Hemispherian presented two posters on GLIX1 at the 31st Society for Neuro-Oncology Annual Meeting, showing robust, dose-dependent antitumor activity across multiple glioblastoma models, including tumor eradication in the SNB19 CDX model and activity in a temozolomide-resistant PDX model where TMZ was ineffective. New preclinical PK/PD data demonstrated confirmed brain penetration at all tested dose levels and dose-dependent increases in tumor 5hmC, a marker of GLIX1's TET2-activating mechanism, correlating with tumor growth inhibition.
Key figures
- Current cohort
- 4
- Clinical trial id
- NCT07464925
- Data readout timing
- first half of 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.